ADDF Awards $6M to Projects Looking to Better Diagnose Alzheimer’s, Dementia

ADDF Awards $6M to Projects Looking to Better Diagnose Alzheimer’s, Dementia
The Alzheimer’s Drug Discovery Foundation (ADDF) announced a second round of research awards totaling about $6 million, part of its Diagnostics Accelerator initiative into better diagnostics for Alzheimer’s (AD) and related dementia. These six global investigative efforts are in various stages of development, and include an advanced blood test for AD diagnosis, genetic-based blood tests, and a tool using retinal imaging technology. Launched in July 2018 with seed funding from Bill Gates and others, the Diagnostics Accelerator seeks to speed development of diagnostics and new biomarkers for early detection of AD and associated disorders, and to promote development of targeted treatments. So far, nearly $10 million in funding has been awarded to 10 scientists worldwide who are developing blood and ocular biomarkers. A first round of awards focused on biomarkers in the blood, eyes, and other fluids and tissues. The initiative is expected to fund $50 million in ADDF awards over the next three years. “Our scientific and business due diligence teams chose these awards based on their promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,” said Howard Fillit, MD, founding ADDF executive director and chief science officer, in a press release. “These awards represent a true collaboration among renowned clinicians who are directly involved with patients and understand the disease, scientists who are developing the tests, and diagnostic companies that understand the regulatory pathways, driving research and product development.” The second round of research awardees include: • Henrik Zetterberg, MD, University of Gothenburg ($3.2 million), Sweden: In collaboration with Roche Diagn
Subscribe or to access all post and page content.